CAV1 and breast carcinoma: Interestingly, we found that the CAV1-deficient cells developed a dramatic resistance to Doxo (a first-line drug for breast cancer) when compared with CAV1-proficient cells (from half-maximal inhibitory concentration [IC50] = 6.62 to IC50 = 51.06) (Figure 6D).